⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 9, 2026Neurology

Real-world Experience With Ozanimod at Two Academic Multiple Sclerosis Centers With Expanded 24-month Data (P4-20.003)

Devon Conway Jessica Cooperrider Jeffrey Lambe Mengke Du Michelle Chu Michael Gatza Corey Cusack Jacqueline Takere Abam Jennifer Reardon Burhan Chaudhry Christina Schroedle Carrie Hersh

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to assess the safety and effectiveness of ozanimod in patients with multiple sclerosis over a two-year period.
Real-world cohort analysis at two academic centers
Follow-up duration of 24 months
Ozanimod showed significant improvements in safety metrics over 24 months
Effectiveness data indicate positive outcomes in multiple sclerosis management

Implication

Evaluates safety and effectiveness of ozanimod in multiple sclerosis, suggesting real-world applicability.

Abstract

To determine safety and effectiveness of ozanimod in a real-world cohort of people with multiple sclerosis (PwMS) with up to two years of follow-up.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Conway et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3d6faef96ed7f056528 https://doi.org/10.1212/wnl.0000000000213291

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-world experience of ozanimod in adults with multiple sclerosisOriginal Research · 2026
2Updated Study Data for Ozanimod in Relapsing Multiple Sclerosis2024
3Long-term Efficacy of the Sphingosine 1-Phosphate Receptor Modulator Ozanimod by Age Category in Patients with Relapsing Multiple Sclerosis: Final Results from Two Phase 3 Trials and an Open-label Extension Trial (P2-6.007)2024
4Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosisHuman Clinical Trial · 2026 · 4 citations
5Safety and Efficacy of Ozanimod in Patients with Early Relapsing Multiple Sclerosis: 1-year Analysis of the ENLIGHTEN Study (P10-6.014)2024